Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neuroscientific Biopharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$48.22 million
P/E Ratio
20.12
Dividend Yield
0.00%
Shares Outstanding
332.58 million
Earnings per share
-0.013
Dividend per share
N/A
Year To Date Return
45.45%
Earnings Yield
4.97%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neuroscientific Biopharmaceuticals Ltd (ASX: NSB)
Latest News
Healthcare Shares
Early success in battling Crohn's Disease has sent this ASX biotech's shares soaring
Healthcare Shares
Here are the 5 best performing ASX biotech shares of 2021
Healthcare Shares
Neuroscientific Biopharmaceuticals (ASX:NSB) share price surges 11% on drug update
Share Gainers
These 3 ASX Healthcare shares have soared over 10% today
Share Gainers
Neuroscientific Biopharmaceuticals (ASX:NSB) share price leaps 11% on study update
Share Market News
Neuroscientific Biopharmaceuticals (ASX:NSB) share price jumps 9% before trading halt
Healthcare Shares
NeuroScientific Biopharmaceuticals (ASX:NSB) share price wobbles on study results
Share Market News
This ASX biotech share is up 20% today
Share Market News
Why this ASX microcap skyrocketed 190% on Tuesday
NSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Neuroscientific Biopharmaceuticals Ltd
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and treatments for neurodegenerative diseases through preclinical studies of patented technologies.
NSB Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 15 Jan 2026 | $0.15 | $-0.01 | -6.25% | 1,095,344 | $0.17 | $0.17 | $0.15 |
| 14 Jan 2026 | $0.16 | $-0.01 | -6.06% | 4,030,906 | $0.17 | $0.18 | $0.16 |
| 13 Jan 2026 | $0.17 | $0.05 | 43.48% | 5,803,773 | $0.16 | $0.18 | $0.15 |
| 08 Jan 2026 | $0.12 | $0.00 | 0.00% | 169,307 | $0.12 | $0.13 | $0.12 |
| 07 Jan 2026 | $0.12 | $0.01 | 9.09% | 686,839 | $0.11 | $0.13 | $0.11 |
| 06 Jan 2026 | $0.11 | $0.01 | 9.52% | 257,683 | $0.11 | $0.12 | $0.11 |
| 05 Jan 2026 | $0.11 | $0.00 | 0.00% | 58,596 | $0.10 | $0.11 | $0.10 |
| 02 Jan 2026 | $0.10 | $-0.01 | -9.09% | 55,642 | $0.11 | $0.11 | $0.10 |
| 31 Dec 2025 | $0.11 | $0.00 | 0.00% | 134 | $0.11 | $0.11 | $0.11 |
| 30 Dec 2025 | $0.11 | $0.01 | 10.00% | 72,402 | $0.10 | $0.11 | $0.10 |
| 29 Dec 2025 | $0.10 | $0.00 | 0.00% | 176,995 | $0.11 | $0.11 | $0.10 |
| 24 Dec 2025 | $0.11 | $0.00 | 0.00% | 102,251 | $0.11 | $0.11 | $0.11 |
| 23 Dec 2025 | $0.10 | $0.00 | 0.00% | 54,859 | $0.10 | $0.10 | $0.10 |
| 22 Dec 2025 | $0.10 | $0.00 | 0.00% | 11,441 | $0.10 | $0.10 | $0.10 |
| 19 Dec 2025 | $0.11 | $0.00 | 0.00% | 152,482 | $0.10 | $0.11 | $0.10 |
| 18 Dec 2025 | $0.11 | $0.00 | 0.00% | 9,921 | $0.11 | $0.11 | $0.11 |
| 17 Dec 2025 | $0.11 | $0.00 | 0.00% | 79 | $0.11 | $0.11 | $0.11 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 27 Jun 2025 | Anton Uvarov | Issued | 2,650,000 | $92,750 |
Placement.
|
| 27 Jun 2025 | Anton Uvarov | Issued | 1,000,000 | $100 |
As advised by the company. Additional services performed
|
| 27 Jun 2025 | Clarke Barlow | Issued | 1,000,000 | $100 |
As advised by the company. Additional services performed
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Paul Damien John Fry | Non-Executive Director | Jun 2025 |
Mr Fry was a former Partner of Ernst and Young and PwC in Australia and Canada and consults to companies in a range of industries. Paul's experience centres around public markets, capital raisings, governance, risk management and corporate transactions. He has been involved with entities listed on the ASX.
|
| Robert Leslie McKenzie | Non-Executive ChairmanNon-Executive Director | Jun 2025 |
Mr McKenzie has over 35 years' experience in corporate and commercial transactions, restructuring and dispute resolution. He has advised companies on mergers and acquisitions; floats; corporate structuring and restructuring; corporate governance; board and meeting compliance and investment and financial structuring. Rob is currently Chairman of the Perron Institute and was previously on the Takeovers Panel.
|
| Dr Anton Uvarov | Non-Executive Director | Nov 2022 |
Dr Uvarov has experience as an equity analyst in the healthcare industry with a focus on the biotechnology sector, both domestically and internationally. Prior to moving to Australia, Anton was with Citigroup Global Markets where he spent two years as a member of a New York based biotechnology team. Dr Uvarov's scientific experience and company knowledge spreads across a variety of therapeutic areas and spectrum of market capitalizations with his interest in early stage biotechnology companies.
|
| Mr Clarke Barlow | Non-Executive Director | Nov 2023 |
Mr Barlow is a Financial Adviser and Capital Markets Specialist with over 20 years' experience in the Financial Services Industry in Australia and the United Kingdom. Mr Barlow has experience providing corporate advisory services for companies listed on the ASX across a variety of industries, with a focus on growth opportunities in the biotechnology, technology, industrial and resources industries.
|
| Dr Linda Friedland | Non-Executive Director | Oct 2023 |
Dr Friedland with over 25 years of experience in clinical medicine and an international advisor to many Fortune and Forbes global companies. She consults with healthcare, biotech, corporate, and financial insitutions. Linda is a non-executive director on several Healthcare boards within Australia and abroad. Among her roles, Dr Friedland is Deputy Chairman of the Neurological Council of Western Australia (NCWA), senior consultant to TargImmune Therapeutics (Basel, Switzerland), co-founder and director of FFD Capital LLC (USA) and Asia- Pacific partner for Camelot BioCapital. An author of seven healthcare-related bestsellers with a career in television and health media, she has developed public health and disease management programs in Asia, USA, Australia, Africa, and the UK and delivered keynote addresses in more than 30 countries
|
| Mr Christopher (Chris) Bryan Achurch | Company Secretary | Feb 2024 |
-
|
| Nathan Smith | Chief Executive Officer |
-
|
|
| Christopher (Chris) Bryan Achurch | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| BNP Paribas Noms Pty Ltd | 26,625,425 | 10.79% |
| Mcrae Technology Pty Ltd | 19,122,262 | 7.75% |
| Citicorp Nominees Pty Limited | 12,944,993 | 5.24% |
| The Trust Company (Australia) Limited <Sbf A/C> | 5,561,704 | 2.25% |
| Goldfire Enterprises Pty Ltd | 4,544,286 | 1.84% |
| Utas Holdings Pty Ltd | 3,954,123 | 1.60% |
| Mr Anton Uvarov | 3,000,000 | 1.22% |
| Ratdog Pty Ltd | 2,857,143 | 1.16% |
| Ecu Holdings Pty Ltd | 2,555,556 | 1.04% |
| J P Morgan Nominees Australia Pty Limited | 2,475,000 | 1.00% |
| Solequest Pty Ltd | 2,411,206 | 0.98% |
| Trevor Burrows Investment Pty Ltd <Trevor Burrows Inv S/F A/C> | 2,300,000 | 0.93% |
| Ice Lake Investments Pty Ltd | 2,250,000 | 0.91% |
| Hsbc Custody Nominees (Australia) Limited | 2,208,912 | 0.89% |
| Charlton Wa Pty Ltd <Tinamara Super Fund A/C> | 2,150,000 | 0.87% |
| Tt Nicholls Pty Ltd <Nicholls Super Fund A/C> | 2,150,000 | 0.87% |
| Mr Edward Joseph Gettingby & Mrs Margaret Mary Gettingby | 2,090,000 | 0.85% |
| Ms Yulia Uvarova <Techinvest Nominees A/C> | 2,000,000 | 0.81% |
| Platinum Reign Pty Ltd | 2,000,000 | 0.81% |
| Massif Holdings Pty Ltd | 1,950,000 | 0.79% |
